Merck: successful phase III trial on Keytruda

(CercleFinance.com) - Merck announced on Wednesday that a Phase III trial of its flagship immunotherapy, Keytruda, has met its primary endpoints in patients with esophageal cancer.


In the study, Keytruda, in combination with chemotherapy, resulted in "superior" progression-free survival compared to standard therapy in patients with locally advanced or metastatic esophageal cancer.

The trial also met its secondary endpoint of showing a "significant" improvement in the objective response rate (the proportion of patients with a complete or partial response), Merck said.


Copyright (c) 2020 CercleFinance.com. All rights reserved.